TOKYO -- Japanese drugmaker Eisai said Wednesday it will invest up to $15 million in C2N Diagnostics, a U.S. biotechnology firm that has developed a blood test for early signs of Alzheimer's disease.
Pharmaceuticals
Japan's Eisai to invest in U.S. Alzheimer's blood testing firm C2N
Expanded use of tests could boost drugmaker's lecanemab medication
Eisai's Alzheimer's drug lecanemab was approved by U.S. and Japanese health officials last year. (Photo by Yuki Nakao)
Read Next
Latest on Pharmaceuticals
